Comparison of high-risk smoldering multiple myeloma
| n = 90* . | n (%) . | Median TTP, mo . | Log-rank P . | 2-y PD, % . | Overall PD, % . | Specificity, % . | Sensitivity, % . | Diagnostic accuracy . | 2-y AUC . | Integrated time-dependent AUC . |
|---|---|---|---|---|---|---|---|---|---|---|
| Mayo Clinic baseline score† | ||||||||||
| 1 | 37 (41) | 96.1 | .0218 | 8 | 32 | |||||
| 2 | 43 (48) | 48.1 | 26 | 44 | ||||||
| 3 | 10 (11) | 24.7 | 50 | 80 | 93 | 25 | 79 | 0.70 | 0.59 | |
| Mayo Clinic evolving score‡ | ||||||||||
| 0 | 10 (11) | 115.2 | <.0001 | 0 | 20 | |||||
| 1 | 34 (38) | 96.1 | 9 | 35 | ||||||
| 2 | 24 (27) | NR | 21 | 33 | ||||||
| 3 | 22 (24) | 21.8 | 50 | 77 | 85 | 58 | 79 | 0.78 | 0.68 | |
| Mount Sinai multivariable score§ | ||||||||||
| 0 | 29 (32) | NR | <.0001 | 3 | 14 | |||||
| 1 | 36 (40) | 77.3 | 11 | 42 | ||||||
| 2 | 17 (19) | 26.3 | 41 | 71 | 86 | 74 | ||||
| 3 or 4 | 8 (9) | 13.4 | 88 | 100 | 99 | 35 | 86 | 0.85 | 0.74 |
| n = 90* . | n (%) . | Median TTP, mo . | Log-rank P . | 2-y PD, % . | Overall PD, % . | Specificity, % . | Sensitivity, % . | Diagnostic accuracy . | 2-y AUC . | Integrated time-dependent AUC . |
|---|---|---|---|---|---|---|---|---|---|---|
| Mayo Clinic baseline score† | ||||||||||
| 1 | 37 (41) | 96.1 | .0218 | 8 | 32 | |||||
| 2 | 43 (48) | 48.1 | 26 | 44 | ||||||
| 3 | 10 (11) | 24.7 | 50 | 80 | 93 | 25 | 79 | 0.70 | 0.59 | |
| Mayo Clinic evolving score‡ | ||||||||||
| 0 | 10 (11) | 115.2 | <.0001 | 0 | 20 | |||||
| 1 | 34 (38) | 96.1 | 9 | 35 | ||||||
| 2 | 24 (27) | NR | 21 | 33 | ||||||
| 3 | 22 (24) | 21.8 | 50 | 77 | 85 | 58 | 79 | 0.78 | 0.68 | |
| Mount Sinai multivariable score§ | ||||||||||
| 0 | 29 (32) | NR | <.0001 | 3 | 14 | |||||
| 1 | 36 (40) | 77.3 | 11 | 42 | ||||||
| 2 | 17 (19) | 26.3 | 41 | 71 | 86 | 74 | ||||
| 3 or 4 | 8 (9) | 13.4 | 88 | 100 | 99 | 35 | 86 | 0.85 | 0.74 |
Patients were required to have all listed variables described for the complete case analysis.
BMPC ≥10%, m-protein ≥3 g/dL, FLCr ≥8.
BMPC ≥20%, eMP (≥10% increase in m-protein and/or immunoglobulin within the first 6 mo and/or ≥25% increase in m-protein and/or immunoglobulin within the first 12 mo), eHb (≥0.5 g/dL decrease within the first 12 mo).
Immunoparesis, eHb GBTM, eMP GBTM, edFLC GBTM.